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 Abstract. This brief overview is intended to shed light on the current drug 
repositioning (also called drug repurposing) in the therapeutics of the 
novel coronavirus disease which emerged in 2019 (COVID-19). In this 
sense, the repositioning drugs for new indications can offer a better risk-
versus-reward trade-off when compared to other drug development 
strategies, given that it makes use of drugs whose safety profile are 
already understood. Nonetheless, this approach allows healthcare 
professionals to promptly tackle the disease by investigating readily 
available drugs against it. 
Keywords: coronavirus; antiviral; pandemic; outbreak; drug repositioning; 
healthcare. 
 
 
1. COVID-19 outbreak and its current scenario 
On December 31st, 2019, several pneumonia 
cases linked to a seafood market in Wuhan, China 
were reported to the World Health Organization 
(WHO). The fast-spreading infection, now known 
as coronavirus disease 2019 (COVID-19), is 
caused by a novel coronavirus (SARS-CoV-2) [1]. 
This recent global outbreak has raised many con-
cerns regarding the limitations of standard 
therapeutic protocols against fast-spreading dis-
eases as well as the importance of their epidemi-
ological characteristics. Regarding the severe 
acute respiratory syndrome, SARS-CoV-2 is the 
etiological agent of the ongoing pandemic of 
2019 CoV disease, which is already responsible 
for far more deaths than were reported during 
the previous public health emergencies of inter-
national concern provoked by two related patho-
genic CoVs from 2002 and 2012 [2]. 
The cases of infection have been continuously 
increasing ever since its outbreak. Currently, 
there are no scientifically reliable approved 
drugs to treat the infection. In this scenario, there 
is a need to utilize the existing repertoire of FDA 
approved drugs to treat the disease [3]. Regard-
ing COVID-19 infection, its symptoms are usually 
flu-like, while non-specific symptoms such as fe-
ver, dry cough and malaise are also common, up 
to the shortness of breath – which is an indicator 
of bad evolution. In this sense, differential diag-
nosis plays a crucial role in determining proper 
patient care, being this goal achieved by point of 
care immunochromatographic tests, real time 
polymerase chain reaction (RT-PCR) or by en-
zyme-linked immunosorbent assay (ELISA) in 
proper lab environment. 
One can find that imaging (CT) could be the an-
swer to the initial assessment of desaturating pa-
tients. The bilateral commitment of the lungs to-
gether with the epidemiological scenario are 
clues to the differential diagnosis, despite testing. 
Such assessment allows differentiation from the 
single lung disorder seen in Influenza patients. 
Notwithstanding, the medical personnel should 
be aware of the potential “cytokine storm” which 
may be caused also by severe Influenza A [4]. Ta-
ble 1 showcases the main specific and unspecific 
symptoms associated to COVID-19. 
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Table 1 – Main specific and unspecific symptoms 
associate to COVID-19 
Symptoms* 
Specific Unspecific 
 Fever 
 Fatigue 
Shortness of breath# Muscle Pain 
# often leads to bilateral lung 
commitment 
Cough 
 Expectoration 
 Headache  
 Hemoptisis 
 Diarrhea  
Notes: All symptoms were thoroughly reported by 
Huang and collaborators in 2020 [5]. 
 
2. Current COVID-19 therapeutics and perspectives 
on drug repurposing 
Although there is up to date no FDA-approved 
specific treatment for COVID-19 infection, ex-
perimental drugs such as favipiravir and hy-
droxychloroquine are gaining increasing atten-
tion due to their allegedly efficacy. Favipiravir is 
a pyrazinecarboxamide derivative derivative 
whose main target is viral RNA-dependent RNA 
polymerase, while hydroxychloroquine is an 
aminoquinoline whose pharmacodynamics of its 
antiviral activity is still unclear. These drugs are 
selected to undergo investigation following em-
pirical in vitro testing, chemoinformatic or other 
in silico approaches which correlate their chemi-
cal structure to biological activity. These methods 
are gaining attention due to their low cost when 
compared to standard medicinal chemistry ap-
proaches and provide reliable data under the 
time constraints imposed by global outbreaks 
such as COVID-19. In this sense, drug repurpos-
ing offers quick insights to employ readily avail-
able drugs against unorthodox biological targets 
[10, 11, 12, 13]. Table 2 summarizes the main 
drugs which are currently under investigation 
against COVID-19. 
 
Table 2 – Drugs under investigation against COVID-19 
Antiviral drug MoA2 Regular indication FDA-S4 References 
IFN-Alfa1 Miscellaneous Hepatitis + [6] 
Lopinavir/ritonavir2 Protease Inhibitor HIV + [11] 
Ribavirin2 Nucleotide analogue Broad spectrum antiviral + [6] 
Chloroquine phosphate1 Miscellaneous Antimalarial + [10] 
Arbidol3 Miscellaneous Influenza - [9] 
Favipiravir2 Nucleotide analogue Influenza - [14] 
Remdesivir2 Nucleotide analogue Ebola - [12] 
Darunavir2 Protease Inhibitor HIV + [13] 
Atazanavir2 Protease Inhibitor HIV + [8] 
DRACOs3 5 Suppress viral RNA synthesis Broad spectrum antiviral - [7] 
Ivermectin1 Miscellaneous Antiparasitic + [15] 
Notes:  
1 Targets viral replication or entry/apoptosis; 2 Targets viral replication; 3 Targets viral entry/apoptosis; MoA – 
Mechanism of Action; 4 FDA-S - FDA status; 5 Double-stranded RNA Activated Caspase Oligomerizer. 
 
Among potential drugs, the nucleotide analogue 
remdesivir is shown to be one of the most prom-
ising and hopeful anti-viral in therapeutic. It 
works by targeting viral RNA-dependent RNA 
polymerase (RdRp) while evading proofreading 
by viral exoribonuclease [16], resulting in prema-
ture termination of viral RNA transcription. 
Unlike other nucleotide analogues, remdesivir is 
a phosphoramidate prodrug with broad-
spectrum activity against many virus families, 
including Orthocoronavirinae, in which the 
pathogenic SARS-CoV and Middle East respira-
tory syndrome coronavirus are included [17, 18]. 
The other nucleotide analogue, RdRp inhibitor 
favipiravir is easily recognized as a substrate of 
viral RNA polymerase in many RNA viruses [19]. 
Recently, preliminary results of clinical studies 
have shown favipiravir to have good potency in 
treatment of Chinese patients with COVID infec-
tion [18]. Favipiravir was approved for the 
treatment of COVID-19 in China in March, 2020. 
In addition, patients with COVID-19 infection are 
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being recruited for randomized trials to evaluate 
the efficacy of favipiravir plus interferon-α 
(ChiCTR2000029600) and favipiravir plus ba-
loxavir marboxil (ChiCTR2000029544) [20]. 
Protease inhibitors (PIs) are important antiviral 
drug agents. In the Orthocoronavirinae context, 
the targets of PIs are papain-like protease and 
3C-like protease [21]. It is noteworthy to men-
tion that [22] compared the efficacy of prophy-
lactic remdesivir as well as therapeutic remde-
sivir with that of LPV/ritonavir - IFNb combina-
tion therapy in a humanized MERS-CoV infection 
model. They observed the efficacy of remdesivir 
was superior to that of LPV/RTV-IFNb against 
MERS-CoV in terms of viral load reduction and 
improvement in extent of pathologic change in 
lung tissue [22]. Chinese Clinical Trial Register 
number, ChiCTR2000029308 failed based on the 
usage of LPV/RTN to provide benefits compared 
to standard care alone, hence there was no dif-
ference in the reduction of viral RNA loading for 
severe SARS-CoV-2 patients [23]. 
Chloroquine was shown to increase endosomal 
pH, which prevents virus/cell fusion. It also inter-
feres with the glycosylation of cellular receptors 
of SARS-CoV. Although the in vitro data of 
chloroquine is promising (EC90 of 6.90 μM, using 
Vero E6 cells infected by SARS-CoV-2), an exten-
sive prescription of chloroquine in clinical treat-
ment of SARS-CoV-2 is a completely off-label use 
[24]. 
Originally identified as an inhibitor of the interac-
tion between the human immunodeficiency vi-
rus-1 (HIV-1) integrase protein (IN) and the im-
portin (IMP) α/β1 heterodimer responsible for 
IN nuclear import [25], Ivermectin is an FDA-
approved broad spectrum antiparasitic agent 
that has since been confirmed to inhibit IN nu-
clear import and HIV-1 replication. Other actions 
of ivermectin have been reported, but ivermectin 
has been shown to inhibit nuclear import of host 
and viral proteins, including dengue virus 
(DENV) non-structural protein 5 [26]. 
The Oswaldo Cruz Foundation (Fiocruz) said in a 
note that it found in research on treatments for 
COVID-19 that the drug Atazanavir, used to treat 
HIV, was able to inhibit viral replication, in addi-
tion to reducing the production of proteins that 
are linked to the inflammatory process in the 
lungs and, therefore, to the worsening of the pa-
tients' clinical condition [27]. 
Considering the lengthy process of approving 
novel drugs to general health practice, the repur-
posing of preexistent medicines is surely a less 
strenuous approach in the path towards prompt 
medical treatment. In this sense, the commer-
cialization of novel compounds in pharmaceuti-
cal formulations is preceded by thorough evalua-
tion of their efficacy and safety profiles through 
several approaches such as in silico, in vitro, 
ex vivo and finally in vivo investigations. This 
process may take about ten years to achieve 
completion [28], while drug repurposing follows 
mainly clinical trials to attest the usefulness of 
the proposed treatment under the light of patient 
safety. Considering that emerging global out-
breaks such as COVID-19 require fast and effi-
cient intervention to counter mass contamina-
tion, drug repurposing is a remarkable alterna-
tive to tackle the epidemy in its beginning. 
This has been a way out for several diseases, for 
instance, Brazilian researchers are working with 
derivatives of triazoles, known antifungals, for 
the treatment of sickle cell anemia. For neglected 
diseases, the repositioning of drugs is an excel-
lent strategy, in which little is invested, or even in 
emergency diseases, such as the current COVID-
19 outbreak [29, 30]. 
 
CONCLUSION 
The repositioning drugs for new indications can 
offer a better risk-versus-reward trade-off when 
compared to other drug development strategies, 
given that it makes use of drugs whose safety 
profile are already understood. Nonetheless, this 
approach allows healthcare professionals to 
promptly tackle the disease by investigating 
readily available drugs against it. However, care 
must be taken and all clinical investigations must 
be performed in order to ensure the efficacy of 
the treatment under the light of patient safety.  
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